[Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
Liver function during continuous subcutaneous deferoxamine therapy was investigated in 29 patients with homozygotic beta-thalassaemia. Average duration of treatment was 26 months (range 8-51 months). A decrease in haemosiderosis and an improvement in liver function was observed in 27 patients: Mean liver density, determined by computed tomography, decreased from 98 to 84 HU, mean serum ferritin concentration fell from 8028 to 3661 ng/ml, mean serum GOT activity from 44 to 13 U/l and GPT from 51 to 16 U/l. Mean cholinesterase activity, reflecting the improved synthetic activity of the liver, increased from 4063 to 4530 U/l.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage*; D006486:Hemosiderosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007279:Injections, Subcutaneous; D008099:Liver / Q000503:physiopathology*; D008111:Liver Function Tests; D013789:Thalassemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D003676:Deferoxamine
Kontinuierliche subkutane Deferoxamin-Behandlung bei Thalassaemia major. Abnahme der Hämosiderose und Besserung der Leberfunktion.